Perspective Therapeutics, Inc. · AMEX:CATX
Perspective Therapeutics — Investor Presentation (January 2024)
86 slides from Perspective Therapeutics's investor presentation, Jan 17, 2024
Slide 1: Corporate Presentation
PERSPECTIVE THERAPEUTICS Corporate Presentation NYSE: CATX
Slide 2: Legal Disclaimers
Legal Disclaimers ‘Ts presentation cartansfomarctoohing statements wihin the meuning of te Unted States Private Secures Ligation Refom Act of 1995. Statements inthis pesetaton thet ae net seems of nstoral act are frwarGoahng sttements. Words suth a8 “ay.” “wil” “sows. “epsct” “pan.” “antepst” “cou,”
Slide 3: Investment Highlights
Investment Highlights Platform radiopharmaceutical company targeting pan-cancer Proprietary chelator-based peplide targeting platform ‘opportunities utilizing 2% generation c-emitter vides engine for pipeline expansion ted in-not manutfa
Slide 4: Platform Expansion Engine
Platform Expansion Engine ‘Two Lead Progams in linicand Broad Proprietary Pipeline Neuroendocrine cancer VMTener Pheoshromeeytomas, paragangliomas Small eal lungeancer vation. Metanoma (MOIR) ‘veT02(PETagent) Melanoma (imagingof MCR) Program3 (Novel peptide) Mutiple soi tumors PSVaoL Radic hyid) Pro
Slide 5: Pipeline With Multiple Expected Near-Term Data Readouts
Pipeline With Multiple Expected Near-Term Data Readouts
Slide 6: Management Team
Management Team Deep Experience in Radiopharmaceuticalsand OncologyDrug Development 20+ yoats of expertise in biotechnology ampenies; pubic and private companies: oncology and nuclear pharmacy Jonathan Hunt Chie Financial Officer 20+ yoats of expertise in financial contols and public ecounting for a
Slide 7: Radiopharmaceuticals are a Pillar of Oncology Treatment
Radiopharmaceuticals are a Pillar of Oncology Treatment Unique Mechanism of Action Offers Pan-Cancer Opportunities Radioligands can precisely deliver radiation drsetly to cancor cols reducing offtargot effects Proven pillar of canoer treatment Perspective's plato technology is optimized for greater
Slide 8: Perspective's Radiopharmaceutical Optimization Process
Perspective’s Radiopharmaceutical Optimization Process Unique Mechanism of Action Offers Pan-Cancer Opportunities Targeting Peptide Engineered for specific recept ensure highly directed uptake Linker Selected to assist peptide binding ‘and optimize clearanc and healthy tissues Isotope 203Pb for SPEC
Slide 9: Lead-212: The Optimal Therapeutic Isotope
Lead-212 (?#2Pb): The Optimal Therapeutic Isotope Alpha Particles Provide Numerous Benefits Over Currently Used Beta Particle Radiotherapies + With a much higher atomic mass, alpha (a)particles generate more energy and travel a shorter distance compared to beta (B) particles, making them more cytoto
Slide 10: Chelator Optimized for Pb
Chelator Optimized for 7/2°°Pb Perspective's Enabling Technology for Po-based Radiopharmaceuticals .. : ee + Designed spectically for Pb isotopes Ho. HN. + Optimized for rapa renal na NET2- “ee NET2+ Ne NETO clearance though neutralized formal charge roa ror Yar raeste’ VD . 3) « Stechlosek te OH Hp
Slide 11: Pb-based Theranostics Enable Both Diagnosis and Targeted Treatment of Cancer
Pb-based Theranostics Enable Both Diagnosis and Targeted Treatment of Cancer Identical Distribution of °°Pb and 2!2Pb for Imaging and Treatment, Respectively Cancer Cell 4 Imaging =p Patient selection Dosimetry: T,,, = 52h spb can Tig? tinker teectansh pharmacokinetics Matches peptide PK Dosimetry:
Slide 12: Neuroendocrine Tumors: VMT-a-NET
Neuroendocrine Tumors: VMT-a-NET Targeting the somatostatin receptor to treat rare neuroendocrine- type cancers a=
Slide 13: VMT-α-NET Currently in Phase 1/2a Studies: Key Facts
VMT-o-NET Currently in Phase1/2a Studies: Key Facts Targeting somatostatin receptor type 2 (SSTR2) for the imaging and treatment of neuroendocrine tumors Initiated first-in-human imaging (2021) & therapy (2022) under compassionate use d Fast Track Designation for first line therapy r Therapeutic Tri
Slide 14: SSTR2 is an Attractive Target for Identifying and Treating Tumors
SSTR2 is an Attractive Target for Identifying and Treating Tumors Expressed Across Several Tumor Types Neuroendocrine tumors (NETS) + Neuroendocrine cells are specialized cells that secrete hormones and other bioactive substances + Neuroendocrine cells are found throughout. the body + Often grow in
Slide 15: Superiority of Perspective's Platform Technology vs Generic Compounds
Superiority of Perspective’s Platform Technology vs Generic Compounds Decreased Off-Target Toxicity, Increased Tumor Uptake and Retention in Preclinical Studies SSTR2 tumor model demonstrates superiority of VMT- «NET to generic compounds 8-fold improved tumor uptake with decreased kidney retention A
Slide 16: VMT-α-NET Shows Significant Improvement vs Standard of Care in Preclinical Models
VMT-o-NET Shows Significant Improvement vs Standard of Care in Preclinical Models ‘Superior Efficacy with Single Dose or Multiple Administrations a “= i f ~ i = “exc ae O coer nar ear ee Yee i aaa oO RE Oa) 8 OB fpf Spee I- i oe pepoveraner MER (1x120 ye) } S (4x30 nei) I oe ae ee t vi 16 | f Srgndm
Slide 17: 203Pb SPECT Imaging Reveals Favorable VMT-α-NET Properties
203Ph SPECT Imaging Reveals Favorable VMT-o-NET Properties" Rapid Tumor Targeting, High Tumor and Renal Clearance Retention + Tumors visible within 1. hour indicates rapid binding to SSTR2 target + High intensity above background implies excellent therapeutic window —~e - 3 3 + Unbound drug in bladd
Slide 18: 212Pb SPECT/CT Imaging Confirms VMT-α-NET Tumor Uptake
222Pb SPECT/CT Imaging Confirms VMT-o-NET Tumor Uptake Diagnosticand TherapeuticShow Same Uptake and Retention Characteristics 202pp SPECT/CT Imaging? 212Pp SPECT/CT Imaging? pt#oo1 PtHo09 + Both? imaged directly using SPI + SPECT/CT shows ve ‘tumor uptake and retention of Pb]VMT-o-NET jours more th
Slide 19: Significant Response After Single Dose of VMT-α-NET
Significant Response After Single Dose of [2!?Pb]VMT-o-NET Metastatic NET Pancreas with Adrenal Crisis - Maximum Intensity Projection (MIP) Tumor Before Treatment ‘Tumor After 1 Dose + 88Ga-DOTA-NOC PET images at base line and post 1st dose of [22Pb]VMT-o-NET & + MIP suggesting strong y i] reduction
Slide 20: Almost Complete Response After Doses of VMT-α-NET
Almost Complete Response After 3 Doses of [7“2Pb]VMT-o-NET Metastatic NET Pancreas with Adrenal Crisis - PET/CT ‘Tumor Before Treatment Tumor After 3 Doses (S.ACTH)~ 790 pg/ml SACTH = 96 pg/ml %» AY penspecrive
Slide 21: Clinical Investigation of VMT-α-NET in Metastatic SSTR2 Positive Patients
Treating Physician: De shita B Sen Director & Head Dept of Nuclear Med {Molecular Imaging Fotis Memorial Research Institute, Gurgeon naa Clinical Investigation of [?'7Pb]VMT-c-NET in Metastatic SSTR2 Positive Patients Interim Resultsas of September 28, 2023, for Ongoinginvestigationin india Current
Slide 22: High Partial Response Rate at Starting Dose in Patients with SSTR+, Late-Stage NETs
High Partial Response Rate at Starting Dose in Patients with SSTR+, Late-Stage NETs Interim Results as of September 28, 2023, for Ongoing Clinical Investigation Program in India Km ex ox REX © errno kre a Pants ° wes kane ex tO rac yok ener Ox abet 7 a > PR eeRCSH oo Ce > soe ve kone ox 9 > vr enon
Slide 23: Trial Design: VMT-α-NET mTPI-2 Phase 1/2a For Neuroendocrine Tumors
Trial Design: [2!Pb]VMT-o-NET mTPI-2‘ Phase 1/2a For Neuroendocrine Tumors Pinay Obie: To detemin te MTO/MFO of P2PUNMEANET(RP20)| maging ‘Aspe SRA PET/CT sea a 25-10 nGidose exeaatin with ned dosing every Escalon ny 1032 Therpeuts Bre Torpies oe " asics: un Ureresae o meta SSTR2 pee NETS Etna Tato
Slide 24: Melanoma Program: VMT01/02
Melanoma Program: VMT01/02 Using the melanocortin receptor MC1R to target melanoma for imaging and therapy
Slide 25: Slide 25
Slide 26: Metastatic Melanoma
Metastatic Melanoma [2*Pb]VMTO1 target indication: MCAR-positive melanoma + Projected market opportunity for melanoma of $8 billion in 2028" + Significant unmet needin the US 4 Liver + ~100K new diagnoses annually? + ~8,000 people die from melanoma every year? skin (aman) + Treatment depends on the
Slide 27: 68Ga VMT02 PET Imaging in Patient with MC1R Positive Metastatic Melanoma
[®Ga]VMT02 PET Imaging in Patient with MC4R Positive Metastatic Melanoma Diagnostic Peptide DemonstratesSimilar Uptake to FDG in Tumors 4F-FDG (Standard of Care) [sGajvro2 Patient information: + Male, Asian, 33 years old + [68Ga]VMTO2: 7 mci injection, 45 min post- injection imaging Clinical Collabo
Slide 28: Combination Targeted Alpha Particle Therapy & Immunotherapy
Combination Targeted Alpha Particle Therapy & Immunotherapy geting ‘Combination with Standard of Care Immunotherapy + Ionizing radiation is an inducer of immunogenic cell death? + Due to their destructive nature, alpha particles are particularly good at generating eoantigens for immuno-sensitization
Slide 29: 212Pb VMT01 in Combination Demonstrates Synergistic Responses
[?Pb]VMTO1 in Combination Demonstrates Synergistic Responses Multiple Melanoma Tumor Models Show Promise of Combining with Standard of Care Key Takeaways High response rates in multiple tested models 43% complete and durable response if combined with immunotherapy ina model highly resistant to check
Slide 30: Trial Design: VMT01-T104 mTPI Phase 1/2a For Metastatic Melanoma
Trial Design: [2“7Pb]VMT01-T104 mTPI1 Phase 1/2a For Metastatic Melanoma PrimaryObjectve: To determine the MTO/MFO of (2PDIVNTOA (RP2D) Imaging, (PD]UMTOL SPEG/CT or [*Ga]voNTOR PET/CT 3-15 mo dose escalation with xed dosing every 8 Screen -120 subjects i eeepenctoe weeks for upto 3 eles Population
Slide 31: Prostate Cancer Program: PSV401
Prostate Cancer Program: PSV401 A differentiated PSMA-targeted radiohybrid molecule for dual PET imaging and targeted alpha therapy
Slide 32: Prostate Cancer Program: PSV401
Prostate Cancer Program: PSV401 differentiated PSMA-targeted radiohybrid molecule for dual PET imaging and targetedalpha therapy PSMA sa clinically and commercially validated target for Diagnostic radioligand therapy Linker in Combines two chelators identical distribution of im ith single targeting,
Slide 33: Manufacturing, Production and Logistics of 212Pb-labeled Therapeutics
Manufacturing, Production and Logistics of 212Pb- labeled Therapeutics The Path to Commercial Supply
Slide 34: 212Pb is Plentiful, Storable, Scalable & Suitable for Distributed Logistics
212Ph is Plentiful, Storable, Scalable & Suitable for Distributed Logistics The supply chainis lowersiskand more robustthan other therapeuticisotopes IsotopeSource Isotope Purification Product Manufacturing, ‘Also produced in industrial nuclear processes Naturally occurring in mining waste Can be ma
Slide 35: Isotope Decay Chain Dictates Supply, Purification, Manufacturing & Logistics
Isotope Decay Chain Dictates Supply, Purification, Manufacturing & Logistics Naturally Occurringlsotope Decay - No Irradiation Processes Required Prentiful Supply: Naturally occurring, or produced as a waste product Chemical Separation: Allows for Ra-based generators of *Pb Chemical Separation from
Slide 36: 212Pb Isotope Purification Without Just-in-time Irradiation
212Pb Isotope Purification Without Justin-time Irradiation ‘Simple chemical separation technology of natural decay products de-risks supply chain Inlet Chromatography column - retains parent but not daughter radionuclide 4 Outlet O 5° oll) B Cc decay 224Ra parent —" el @ Immobilized |@ Accumulation
Slide 37: 212Pb Supply via Reusable Desktop Isotope Generator
212Pbh Supply via Reusable Desktop Isotope Generator VMT-a-GEN + Extensive feedstock from nuclear and mining waste material + Long-term supply contract secured with US DOE + On demand daily doses — Auto-regenerates overnight — ~Lweek shelf life te ‘Small, Elegant 242Pb Isotope Generator \ y) + Integ
Slide 38: Scalable Manufacturing and Distribution Logistics
Scalable Manufacturing and Distribution Logistics Perspective'splan to flexibly scale manufacturing to commercial levels (100,000+ doses per year) (Generator Manutacurer ‘COMO. [ste | E re Generator gay manufactures a. Senereion andsnppea eutector2P recowo G eS ono Raco-syrtness pm one ‘Mooue 5] fat
Slide 39: Isotope Decay Chain Dictates Supply, Purification, Manufacturing & Logistics
Isotope Decay Chain Dictates Supply, Purification, Manufacturing & Logistics Naturally Occurring Isotope Decay - No Irradiation Processes Required + Cena continental supply + Fluted week for Ra + Distibuted continentaty + Eluted day for2P0, + Daily manufacture ofinished doses + Leverages existingnet
Slide 40: Infrastructure and Distribution Networks for Radiopharmaceuticals are Mature
Infrastructure and Distribution Networks for Radiopharmaceuticals are Mature Existing radiopharmacies have established logistics for distributed supply ‘Map of US Radiopharmacies* + There were 40+ million diagnostic nuclear medicine procedures performed in the US in in 2022 + Multiple networks exist
Slide 41: Regional Manufacturing Allows Commercialization of 212Pb-labeled Finished Products
Regional Manufacturing Allows Commercialization of 27Pb-labeled Finished Products Limited number of sites allows for “network effect” to ensure robust supply chain Location cus Coralie. 1A sim NewYork. NY 15m Los Angeles. CA 46m Astin, 32m ‘ianta, GA 57m Central Florida, FL 25m Proposed oes ‘op 6 si
Slide 42: Strong Intellectual Property Portfolio
Strong Intellectual Property Portfolio Fully Licensed University/Perspective owned IP 4 provisional patents + Composition of Matter and Use radiometal separations technology, novel pan-cancer product . generator technologies (US., EU. Australia) 3 non-provisional patent applications, + Composition o
Slide 43: Appendix
Appendix
Slide 44: Targeting cancer from the inside out
Targeting cancer from the inside out We are developing game-changing Precision Medicine Therapeutics which harness the power of targeted Alpha-Particle Radiotherapies that make an impactful difference for cancer patients and the clinicians Who treat them.
Slide 45: Who We Are
Who WeAre Perspective Therapeutics (NYSE-CAD)is a clinical stage precision medicine company, debuting as a public company in 2023. With a broad pipeline and two priortized lead programsin clinic, we are disrupting traditional radiation therapy treatment for cancer though developinga new class of ima
Slide 46: α-Particles Have Superior Tumor Killing Properties vs. β-Particles
a-Particles Have Superior Tumor Killing Properties vs. B-Particles Higher atomic mass Lethal double-stranded DNA breaks DNA repair mechanisms overwhelmed More Powerful Effects Than ‘Approved B Therapy ARARMMEREE Oep0sit energy over 3.5 cell diametersvs. beta particles (up t0-200 cells) Targeted Cell
Slide 47: Lead-212: The Optimal Therapeutic Isotope
Lead-212 (*!2Pb): The Optimal Therapeutic Isotope Greater Therapeutic Energy Expected to Improve Outcome with Better Safety Alpha particle range (up to 3 cell diameters) Beta range (up to 200 cell diameters) Tumor Colts Normal Tissue oN A SY ome amm 0mm Tumor Healthy tissue mi a=
Slide 48: Lead (Pb): The Ideal Theranostic Isotope
Lead (Pb): The Ideal Theranostic Isotope 09/212Pb & Perspective Chelator ‘deal agreement between imaging’and therapeutic compounds =P and Pb matched pair Readily avilable isotope Generator produced Ideal chelator Proprietary chelator carries O net charge Rapid clearance rom blood Conjugation to smal
Slide 49: Peptides are Ideal Ligands for Radiopharmaceutical Therapy
Peptides are Ideal Ligands for Radiopharmaceutical Therapy Monoclonal anti eptides Tunerserevaton: | Low Wanuactunng: | Complex boa! Tamer panatn: | Hey enwactns: | sytnate esance epatoiy ther) | | ones Hen ‘earanee: Reraiieya) | | cus vewow Belogeal Ste | Long Bologea t2tze | short Target arity Hn
Slide 50: VMT-α-NET is Developed to Address the Unmet Need in NETs
VMT-a-NET is Developed to Address the Unmet Need in NETs CurrentStandard of Care limited to subset of NETs patients NETTER- Study Finaloveralsurvival® Significant unmet need: + ~12K new diagnoses annually in the US* meer + ~175,000+ people are living with this diagnosis in the US Market Opportunity
Slide 51: 225Ac Isotope Decay Chain and Potential for Off-Target Toxicity
225A\c Isotope Decay Chain and Potential for Off-Target Toxicity ‘Alpha-particle emission Q OH sora ioheat core = me No’ ‘fypn91 812E 40 sy yenUEIeG
Slide 52: Isotope Decay Chain - Product Implications
Isotope: Decay chain - Product implications Postfinal radiolabelingand purification, alpha and beta emitting daughters of 2°Ac build up fast. Dose Vial Free MAC225 wFr221 mALDIT mBL213 = T1209 mP0213 Radiometals: 239 —> a. agi —- 8 oat —> a Fp —> a Radioactivity (Bq) Labeled i — a. To Post Final 4h
Slide 53: 212Pb Isotope Decay Chain and Importance of the Pb-Specific Chelator
212Ph Isotope Decay Chain and Importance of the Pb-Specific Chelator ‘where the drug goes = where the 0 alpha particle Is deposited OH OH + Perspective’s proprietary chelator retains 98% of 2228) after transition in drug formulation + Generic chetatorsleak the “2Bi alpha-emitting daughter up to 36%!
Slide 54: Clinical Investigators and Advisors
Geoffrey B. Johnson MD. PhD (Chair, Dvision of Nuclear Medicine (Chair, PET/MARED Associate Professor Departments of Rasilogy ‘and Immunology Mayo Ginio~ Rechestor, MN Vikas Prasad MD BW Professor of Radiology bash Associate Professor Radiology Oison of Nuclear Medicine Washington University int Lou
Slide 55: Appendix: VMT-α-NET
Appendix: VMT-o-NET
Slide 56: Significant Tumor Response After Two Doses
Significant Tumor Response After Two Doses Patient 3: Metastatic NET Pancreas with Liver Metastases MIP image Before Treatment MIP image After 2nd Treatment Liver Metastases after treatment with two doses
Slide 57: Reduction in Size of Necrotic Masses After Doses
Reduction in Size of Necrotic Masses After 2 Doses Patient 5: Pancreatic NET Tumor Before Treatment TumorAfter Treatment
Slide 58: Favorable Safety and Tolerability Profile
Favorable Safety and Tolerability Profile FourMonths Post-Treatment(5 Patients) Hemoglobin Levels Total Leukocyte Count Oe ; SSS
Slide 59: Serious Adverse Event in Patient
Serious Adverse Event in Patient 2 ‘Myelodysplastic syndrome (MDS) Unrelated to Study Drug Patient Profile + 79 yearmale + Metastatic Medullary Carcinoma thyroid " + Received total 3 doses of [2!2Pb]VMT-o-NET therapy i a [3 at an interval of 8 weeks (Cumulative dose 9.6 mCi) , + Developed MDS on rou
Slide 60: Serious Adverse Event in Patient
Serious Adverse Event in Patient 6 Acute Cardiac Event Unrelated to Study Drug ‘Significanttumor burden Patient Profile 25 yearmale Metastatic NET-pancreas Longstanding disease (>6 years duration) Heavily pre-treated with Inj. Sandostatin and 4 oycles of *7’Lu- DOTATATE along with CAPTEM regimen Rec
Slide 61: Appendix: Prostate Cancer Program - PSV401
Appendix: Prostate Cancer Program - PSV401
Slide 62: Typical Theranostic Approach: One Molecule, One Chelator, One Isotope
Typical Theranostic Approach : One Molecule, One Chelator, One Isotope Separate But Chemically Identical Molecules Labeled with Either2™Pb or 2!2Pb for Imagingand Treatment, Respectively Imaging es One chelator 24 hours Cancer Cell 20h One isotope 4 Patient selection T Dosimetry: T,,, = 52h Tagstto
Slide 63: PSV401 DoubLET: One Molecule, Two Chelators, Four Possible Isotopes
PSV401 DoubLET*2: One Molecule, Two Chelators, Four Possible Isotopes (One Molecule Labelled with Two Elementsat Once, with Isotope Selection Determining Diagnosticor Therapeutic. Two chelators on one targeting ligand Each can be labeled with stable or radioactive atoms Diagno: her Enables the s (@2
Slide 64: PSV401 Has Potential to be Best-in-Class Prostate Cancer Targeted Alpha Therapy
PSV401 Has Potential to be “Best4n-Class” Prostate Cancer Targeted Alpha Therapy CurrentStandard of Care with Beta-Based Radiopharmaceutical Therapy (RPT) Still Requires Improvement Significant Unmet Need: VISION Study Overall survival + =288Knew diagnoses annually in the US* + ~3.3M+men ving with t
Slide 65: PSV401: Preclinical Cu PET Imaging Data Showing Tumor Uptake
PSV401: Preclinical Cu PET Imaging Data Showing Tumor Uptake Rapid Tumor Uptake and Effective Renal Clearance with Radioactive Imaging |sotope* Key Takeaways PSMA+ LNCaP tumor 15 min p.i. 30 min p.i. 60 min p.i model suggests A, (4cu]PSv401 targets Coronal Sagittal Coronal Sagittal Coronal Sagittal
Slide 66: PSV401: Preclinical Comparison to Industry Standard
PSV401: Preclinical Comparison to Industry Standard* *CuJPSV401 Compares Favorably to FDA-Approved Imaging Agent [Ga]PSMA-11 (ILLUCCIX®, Telix)? 15 min pi. 30 min pi 60 min pi. 120 min p.i. Coronal Sagittal Coronal “Sagittal Coronal ‘Sagittal Coronal Sagittal Coronal Suv. 4 o Coronal Sagittal Corona
Slide 67: PSV401: Preclinical Comparison to Industry Standard
PSV401: Preclinical Comparison to Industry Standard (*Cu]PSV401 Significantly" Improved Uptake/Clearance Compared to [°°Ga]PSMA11? Tuer Retention Salivary Gland tention = Poapswaat ‘ T peypetaon oapsunat st). es 312), 7 pemrswor Be s° 3 } a + fd Fe (Poopoueas a Bis 4 T Pevpavaos pan =: L 2 . oF . »
Slide 68: Preclinical 212Pb PSV401 Therapy
Preclinical [7“2Pb]PSV401 Therapy Preliminary [22Pb]PSV401 Data Shows Potentialto Effectively Kill Tumors ! + Allimaging performed with [°*Cu]PSV401 microPET + Treatment of PSMA+ prostate cancer xenograft with (22Pb]PSV401 reduced tumor size 38% in 3 days and complete response after 9 days + Additio
Slide 69: Mayo Clinic Inventors
Mayo Clinic Inventors LicensingContinuesa Long & Productive Alliance ‘Mukesh Pandey, PhD, FRSC Decor, Mayo Clini Molecular Imaging Research Program Professor of Radiology Mayo Clinic ~ Rochester, MN Geoffrey B Johnson MD, PhD (Chir, Division of Nuclear Medicine Associate Diector ofthe Mayo Cine Comp
Slide 70: Appendix: Manufacturing, Production and Logistics of 212Pb-labeled Therapeutics
Appendix: Manufacturing, Production and Logistics of 212Pb4abeled Therapeutics
Slide 71: Isotope Decay Chain Dictates Supply, Purification, Manufacturing & Logistics
Isotope Decay Chain Dictates Supply, Purification, Manufacturing & Logistics ‘Naturally Occurring Isotope Decay-No Irradiation Processes Required Plentiful Supply: Naturally occuring, or produced as a waste product, Chemical Separation ‘Allows for Ra-based ‘generators of Pb Chemical Separation from
Slide 72: Parent Isotope Source
Parent Isotope Source Key Isotopes for Supply:225Th and?*Ra 2287h half-life of 1.9 years allows ong term storage and extraction of daughter 2Ra 224Ra grows in naturally (without irradiation) from 22°Th decay Perspective currently has a 10 year supply agreement with US Department of Energy Produced a
Slide 73: Flexible and Scalable Isotope Supply
Flexible and Scalable Isotope Supply 24Rq enables Regional Manufacturing Hubs 224Ra hallt-life of 3.6 days allows weekly + Perspective’s proprietary shipments to regional manufacturing sites \VMT-a-GEN enables shipping of isotope and purification of 2%2Pb in one package, simplifying supply + VMF-a-G
Slide 74: Isotope Decay Chain Dictates Supply, Purification, Manufacturing & Logistics
Isotope Decay Chain Dictates Supply, Purification, Manufacturing & Logistics Naturally Occurring Isotope Decay - No Irradiation Processes Required + Cena continental supply + Fluted week for Ra + Distibuted continentaty + Eluted day for2P0, + Daily manufacture ofinished doses + Leverages existingnet
Slide 75: 212Pb is Plentiful, Storable, Scalable & Suitable for Distributed Logistics
212Ph is Plentiful, Storable, Scalable & Suitable for Distributed Logistics The supply chainis lowersiskand more robustthan other therapeuticisotopes IsotopeSource Isotope Purification Product Manufacturing, ‘Also produced in industrial nuclear processes Naturally occurring in mining waste Can be ma
Slide 76: Parent Isotope Source
Parent Isotope Source + Storage of thorium-228 (half-life of 1.9 years) allows for “on-demand” purification of Ra-224 and Pb-212 + Multiple purfication/production methods for Th-228 with different starting materials and processes, including Ra-228 generators (half- life 5.7 years) + Ra-224 (half-lif
Slide 77: Parent Isotope Supply
Parent Isotope Supply Producedasa waste product, 10s of Ci 7 available + Thorium-228 is available as a natural isotope buts also produced as a waste product from the nuclear fuel cycle, and as a result of production Of therapeutic isotope Ra-223 (marketed as Xofigo, Bayer) Both Ac-27 (the parent iso
Slide 78: Pb-212 Isotope Purification
Pb-212 Isotope Purification + Similar in size to Ga-68 generators + “Desktop” generators + Hot cell sized generators + Useful for prectinical R&D and clinical tials + Useful for cinical tals &limited commercial + For commercial production ‘+ Nimble, portable supply available foreither production ‘+
Slide 79: 212Pb Supply via Reusable Desktop Isotope Generator
212Pbh Supply via Reusable Desktop Isotope Generator VMT-a-GEN + Extensive feedstock from nuclear and mining waste material + Long-term supply contract secured with US DOE + On demand daily doses — Auto-regenerates overnight — ~Lweek shelf life te ‘Small, Elegant 242Pb Isotope Generator \ y) + Integ
Slide 80: Scalable Manufacturing and Distribution Logistics
Scalable Manufacturing and Distribution Logistics Perspective'splan to flexibly scale manufacturing to commercial levels (100,000+ doses per year) (Generator Manutacurer ‘COMO. [ste | E re Generator gay manufactures a. Senereion andsnppea eutector2P recowo G eS ono Raco-syrtness pm one ‘Mooue 5] fat
Slide 81: Slide 81
Slide 82: Slide 82
Slide 83: Slide 83
Slide 84: Slide 84
Slide 85: Slide 85
Slide 86: Slide 86
Perspective Therapeutics — Investor Presentation (January 2024) on 6ix